Business
Cuprina Appoints Dr. Ronald Sherman, Leader in Maggot Debridement Therapy, as Medical and Scientific Director; Secures FDA-approved Medical Maggot License for U.S. Market
SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced that Dr. Ronald A. Sherman, a leading innovator in the use of medical maggots to treat chronic wounds, has agreed to join the Company as Medical an
About this update from Cuprina Holdings (cayman) Limited
[{"type":"image","alt":"Cuprina Holdings (Cayman) LTD","displaySize":"","headline":null,"caption":"Cuprina Holdings (Cayman) LTD","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/402f43f30f35f5ccdd587985aebd2fe7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Vs5DV_xDy69c4LSgVE319A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/402f43f30f35f5ccdd587985aebd2fe7","width":300,"height":73}},"lazy":false},{"type":"text","content":"SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced that Dr. Ronald A. Sherman, a leading innovator in the use of medical maggots to treat chronic wounds, has agreed to join the Company as Medical and Scientific Director in September 2025.","length":540,"tagName":"p"},{"type":"text","content":"Cuprina also announced it has signed an agreement with Dr. Sherman licensing his 2004 FDA clearance to market Lucilia sericata Medical MaggotsTM, the first such marketing clearance in US history. This agreement gives Cuprina the right to manufacture, sell, use and distribute these maggots and associated dressings for use in maggot debridement therapy (MDT) in the United States.","length":385,"tagName":"p"},{"type":"text","content":"Upon joining Cuprina, Dr. Sherman’s roles and responsibilities are expected to include the following:Clinical Leadership on Bio-Therapeutics:","length":142,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Serve as clinical and key opinion leader on maggot therapy, leech therapy, ichthyotherapy, and other company bio-therapeutic initiatives; and","length":141,"tagName":"p"}]},{"val":[{"type":"text","content":"Provide mentorship, insights, and scientific guidance to Cuprina and affiliated clinicians in adopting and expanding bio-therapeutic practices.","length":143,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":284,"olType":false},{"type":"text","content":"Training, Education and Awareness:","length":34,"tagName":"p"},{"type":"list","item...